A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Pneumococcal Infections, sponsored by Pfizer. Completed at 59 sites in 3 countries. Open to participants aged 68 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-16.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 19 in phase 3, and was the 6th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 68 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 2 started in 2008.
This study's enrollment of 1,053 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 19th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2008, is one of 33 in phase 3, and was the 16th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study enrollment.
MAIN INCLUSION CRITERIA:
MAIN EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
13-valent Pneumococcal Conjugate Vaccine
Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Percentage of Participants With Pre-specified Local Reactions
Local reactions were collected by the participant using an electronic diary. Redness and swelling scaled as any(present); mild(2.5-5.0 centimeters\[cm\]); moderate(5.1-10.0 cm); severe(\>10.0cm). Pain as any(present); mild(present, no interference with activity); moderate(present, some interference with activity); severe(present, prevents daily activity). Limitation of arm movement as any(present); mild(present, could move arm above head); moderate(could move arm above shoulder but not above head); severe(could not move arm above shoulder). Participants may be represented in more than 1 category.
Time frame: Days 1 through 14
Percentage of Participants With Pre-specified Systemic Events
Systemic events were collected by participant using electronic diary. Fatigue,headache,new/aggravated generalized muscle pain,new/aggravated generalized joint pain: any, mild(no interference with activity), moderate(some interference with activity), severe(prevents routine daily activity). Fever(\>=38 degrees Celsius\[C\]), chills, rash, vomiting(mild:1-2 times daily; moderate:\>2 times daily; severe:prevents daily activity) decreased appetite \& diarrhea(mild:2-3 loose stools/day; moderate:4-5 loose stools/day; severe:\>=6 loose stools/day) reported. Participants may be represented in \>1 category.
Time frame: Days 1 through 14
Percentage of Participants Taking Pain or Antipyretic Medication
Use of pain or antipyretic medication was collected by the participants using an electronic diary.
Time frame: Days 1 through 14
| Milestone | 13vPnC |
|---|---|
| Started | 1053 |
| Treated | 1049 |
| Completed | 1040 |
| Not completed | 13 |
| Withdrew: Death | 3 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Assigned, not treated | 4 |
Local reactions were collected by the participant using an electronic diary. Redness and swelling scaled as any(present); mild(2.5-5.0 centimeters\[cm\]); moderate(5.1-10.0 cm); severe(\>10.0cm). Pain as any(present); mild(present, no interference with activity); moderate(present, some interference with activity); severe(present, prevents daily activity). Limitation of arm movement as any(present); mild(present, could move arm above head); moderate(could move arm above shoulder but not above head); severe(could not move arm above shoulder). Participants may be represented in more than 1 category.
| Percentage of Participants | 13vPnC |
|---|---|
| Redness: Any (n=666) | 14.3 (11.7 to 17.2) |
| Redness: Mild (n=660) | 12.6 (10.1 to 15.3) |
| Redness: Moderate (n=649) | 6.5 (4.7 to 8.6) |
| Redness: Severe (n=638) | 1.1 (0.4 to 2.2) |
| Swelling: Any (n=664) | 12.8 (10.4 to 15.6) |
| Swelling: Mild (n=658) | 10.9 (8.7 to 13.6) |
| Swelling: Moderate (n=651) | 5.5 (3.9 to 7.6) |
| Swelling: Severe (n=636) | 0.6 (0.2 to 1.6) |
| Pain: Any (n=777) | 51.0 (47.4 to 54.5) |
| Pain: Mild (n=770) | 49.4 (45.8 to 52.9) |
| Pain: Moderate (n=656) | 9.0 (6.9 to 11.4) |
| Pain: Severe (n=634) | 0.2 (0.0 to 0.9) |
| Limitation of arm movement: Any (n=679) | 16.2 (13.5 to 19.2) |
| Limitation of arm movement: Mild (n=674) | 14.8 (12.2 to 17.7) |
| Limitation of arm movement: Moderate (n=636) | 1.6 (0.8 to 2.9) |
| Limitation of arm movement: Severe (n=640) | 1.6 (0.8 to 2.9) |
| Any local reaction (n=802) | 56.6 (53.1 to 60.1) |
| Any severe local reaction (n=643) | 2.6 (1.5 to 4.2) |
Systemic events were collected by participant using electronic diary. Fatigue,headache,new/aggravated generalized muscle pain,new/aggravated generalized joint pain: any, mild(no interference with activity), moderate(some interference with activity), severe(prevents routine daily activity). Fever(\>=38 degrees Celsius\[C\]), chills, rash, vomiting(mild:1-2 times daily; moderate:\>2 times daily; severe:prevents daily activity) decreased appetite \& diarrhea(mild:2-3 loose stools/day; moderate:4-5 loose stools/day; severe:\>=6 loose stools/day) reported. Participants may be represented in \>1 category.
| Percentage of Participants | 13vPnC |
|---|---|
| Fever (any): >=38 degrees C (n=641) | 2.0 (1.1 to 3.4) |
| Fever: >=38 degrees C but <38.5 degrees C (n=636) | 0.8 (0.3 to 1.8) |
| Fever: >=38.5 degrees C but <39 degrees C (n=634) | 0.0 (0.0 to 0.6) |
| Fever: >=39 degrees C but <=40 degrees C (n=635) | 0.3 (0.0 to 1.1) |
| Fever: >40 degrees C (n=638) | 0.9 (0.3 to 2.0) |
| Fatigue: Any (n=733) | 34.4 (30.9 to 37.9) |
| Fatigue: Mild (n=710) | 28.7 (25.4 to 32.2) |
| Fatigue: Moderate (n=683) | 15.2 (12.6 to 18.1) |
| Fatigue: Severe (n=639) | 2.0 (1.1 to 3.5) |
| Headache: Any (n=702) | 26.1 (22.9 to 29.5) |
| Headache: Mild (n=696) | 24.1 (21.0 to 27.5) |
| Headache: Moderate (n=655) | 9.0 (6.9 to 11.5) |
| Headache: Severe (n=637) | 0.8 (0.3 to 1.8) |
| Chills (n=651) | 7.5 (5.6 to 9.8) |
| Rash (n=658) | 8.4 (6.4 to 10.7) |
| Vomiting: Any (vomiting present; n=638) | 0.9 (0.3 to 2.0) |
| Vomiting: Mild (1 to 2 times in 24 hours;n=637) | 0.8 (0.3 to 1.8) |
| Vomiting: Moderate (>2 times in 24 hours;n=635) | 0.2 (0.0 to 0.9) |
| Vomiting: Severe (prevents routine activity;n=634) | 0.0 (0.0 to 0.6) |
| Decreased appetite (n=668) | 11.2 (8.9 to 13.9) |
| Diarrhea: Any (diarrhea present; n=684) | 14.5 (11.9 to 17.3) |
| Diarrhea: Mild (2 to 3 loose stools/day; n=678) | 12.8 (10.4 to 15.6) |
| Diarrhea: Moderate (4 to 5 loose stools/day;n=644) | 3.4 (2.2 to 5.1) |
| Diarrhea: Severe (>=6 loose stools/day; n=635) | 0.3 (0.0 to 1.1) |
| New generalized muscle pain: Any (n=700) | 25.3 (22.1 to 28.7) |
| New generalized muscle pain: Mild (n=679) | 20.5 (17.5 to 23.7) |
| New generalized muscle pain: Moderate (n=658) | 7.9 (6.0 to 10.2) |
| New generalized muscle pain: Severe (n=636) | 0.6 (0.2 to 1.6) |
| Aggravated generalized muscle pain: Any (n=669) | 12.3 (9.9 to 15.0) |
| Aggravated generalized muscle pain: Mild (n=650) | 7.5 (5.6 to 9.8) |
| Aggravated generalized muscle pain:Moderate(n=655) | 6.4 (4.7 to 8.6) |
| Aggravated generalized muscle pain: Severe (n=639) | 1.4 (0.6 to 2.7) |
| New generalized joint pain: Any (n=665) | 12.8 (10.3 to 15.6) |
| New generalized joint pain: Mild (n=651) | 8.1 (6.2 to 10.5) |
| New generalized joint pain: Moderate (n=648) | 5.7 (4.1 to 7.8) |
| New generalized joint pain: Severe (n=637) | 0.8 (0.3 to 1.8) |
| Aggravated generalized joint pain: Any (n=661) | 9.7 (7.5 to 12.2) |
| Aggravated generalized joint pain: Mild (n=647) | 5.7 (4.1 to 7.8) |
| Aggravated generalized joint pain: Moderate(n=647) | 5.1 (3.5 to 7.1) |
| Aggravated generalized joint pain: Severe (n=637) | 1.1 (0.4 to 2.3) |
| Any systemic event (n=832) | 58.4 (55.0 to 61.8) |
Use of pain or antipyretic medication was collected by the participants using an electronic diary.
| Percentage of Participants | 13vPnC |
|---|---|
| Use of medication to treat pain (n=677) | 17.0 (14.2 to 20.0) |
| Use of medication to treat fever (n=655) | 6.4 (4.7 to 8.6) |
Collected over Local reactions, systemic events recorded within 14 days post vaccination. AEs recorded from Visit(V) 1 to 2(29-43 days after V1). At V3(166-194 days after V1), only newly diagnosed chronic medical conditions recorded as AEs. SAEs recorded from V1 to V3.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC: Visit 1 to Visit 2 | — | 10/1,049 (1%) | 486/1,049 (46.3%) |
| 13vPnC: 6-month Follow-up | — | 41/1,049 (3.9%) | 77/1,049 (7.3%) |
| Event | 13vPnC: Visit 1 to Visit 2 | 13vPnC: 6-month Follow-up |
|---|---|---|
| Myocardial infarctionCardiac disorders | 0/1049 | 3/1049 |
| PneumoniaInfections and infestations | 0/1049 | 3/1049 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/1049 | 3/1049 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/1049 | 0/1049 |
| Atrial fibrillationCardiac disorders | 0/1049 | 2/1049 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1049 | 2/1049 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/1049 | 2/1049 |
| BradyarrhythmiaCardiac disorders | 1/1049 | 1/1049 |
| TachyarrhythmiaCardiac disorders | 1/1049 | 0/1049 |
| GastritisGastrointestinal disorders | 1/1049 | 0/1049 |
| Event | 13vPnC: Visit 1 to Visit 2 | 13vPnC: 6-month Follow-up |
|---|---|---|
| Pain (any)Skin and subcutaneous tissue disorders | 396/777 | — |
| Pain (mild)Skin and subcutaneous tissue disorders | 380/770 | — |
| Fatigue (any)General disorders | 252/733 | — |
| Fatigue (mild)General disorders | 204/710 | — |
| Headache (any)General disorders | 183/702 | — |
| New generalized muscle pain (any)General disorders | 177/700 | — |
| Headache (mild)General disorders | 168/696 | — |
| New generalized muscle pain (mild)General disorders | 139/679 | — |
| Limitation of arm movement (any)Skin and subcutaneous tissue disorders | 110/679 | — |
| Fatigue (moderate)General disorders | 104/683 | — |
| Age Continuous(years) | 13vPnC |
|---|---|
| Mean | 75.3 ± 5.1 |
| Sex: Female, Male(Participants) | 13vPnC |
|---|---|
| Female | 584 |
| Male | 465 |
The record gives a start of May 2008, a primary completion of Apr 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 2 years 5 months after primary completion. A results delay was requested in Mar 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine